Study finds that Gardasil is ‘More Cost Effective’ than Cervarix

According to new data published in the British Medical Journal, the cervical cancer vaccine, Gardasil, produced by Merck and Sanofi, may be more cost effective than its competitor GlaxoSmithKline’s Cervarix. However, the differential benefits of both vaccines remain unclear, say researchers from the Health Protection Agency. The study has been updated from the one previously

Continue Reading

European Medicines Agency restricts use of Sanofi’s Multaq

European regulators have decided to restrict use of Sanofi’s anti-arrhythmic Multaq. In July, the French drugmaker discontinued the PALLAS trial in patients with permanent atrial fibrillation, different from the population with non-permanent AF for which Multaq (dronedarone) is currently approved. A significant increase in cardiovascular events was seen in the dronedarone arm, so the study

Continue Reading